Abstract
If nephrolithiasis (NL) promotes progression to end stage renal disease (ESRD), requiring renal replacement therapy, one might expect a higher prevalence of pre-ESRD stones among ESRD versus non-ESRD subjects. We compared the prevalence of pre-ESRD stones in an African-American (AA) hemodialysis (HD) population to the estimated stone prevalence in a nationally representative cohort of AA persons as obtained by the Third National Health and Nutrition Survey (NHANES III). Face-to-face questionnaires were administered to a sample of 300 AA HD patients undergoing dialysis therapy at the University of Chicago to determine pre-ESRD NL prevalence. All data on pre-ESRD stone prevalence was confirmed by documented medical history, radiology and laboratory findings, where available. Prevalence of pre-ESRD NL in AA HD patients was 8.3% versus 2.8% in the age, race and sex adjusted NHANES III population (P < 0.001). After adjustment for age and sex, it was estimated that the prevalence of pre-ESRD kidney stones among AA HD patients is significantly higher than the prevalence of kidney stones found in the general AA population.
Similar content being viewed by others
References
Oren A, Husdan H, Cheng PT, Khanna R, Pierratos A, Digenis G, Oreopoulos DG (1984) Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney Int 25:534–538
Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823
USRDS (2003): the United States Renal Data System. Am J Kidney Dis 42:1–230
Hsu CY, Lin F, Vittinghoff E, Shlipak MG (2003) Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 14:2902–2907
Lewandowski S, Rodgers A, Schloss I (2001) The influence of a high-oxalate/low-calcium diet on calcium oxalate renal stone risk factors in non-stone-forming black and white South African subjects. BJU Int 87:307–311
Evan AP, Lingeman JE, Coe FL, Shao Y, Parks JH, Bledsoe SB, Phillips CL, Bonsib S, Worcester EM, Sommer AJ, Kim SC, Tinmouth WW, Grynpas M (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576–591
Worcester EM, Parks JH, Evan AP, Coe FL (2006) Renal function in patients with nephrolithiasis. J Urol 176:600–603; discussion 603
Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607–616
National Center for Health Statistics (1996): Third National Health and Nutrition Examination Survey, Documentation (catalog number 76200), Hyattsville, MD, US Department of Health and Human Services (DHHS)
National Center for Health Statistics (U.S.) (1996) The Third National Health and Nutrition Examination Survey (NHANES III, 1988–94) reference manuals and reports. U.S. Dept. of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics; Supt. of Docs. U.S. G.P.O. distributor, Hyattsville, MD, Washington DC
Jungers P, Joly D, Barbey F, Choukroun G, Daudon M (2004) ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 44:799–805
Vupputuri S, Soucie JM, McClellan W, Sandler DP (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222–228
Worcester E, Parks JH, Josephson MA, Thisted RA, Coe FL (2003) Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int 64:2204–2213
Gillen DL WE, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67:685–690
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stankus, N., Hammes, M., Gillen, D. et al. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res 35, 83–87 (2007). https://doi.org/10.1007/s00240-007-0079-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-007-0079-3